« Back
Home /
Certepetide

Certepetide

Item no.	HY-P3448-1mg
Manufacturer	MedChem Express
CASRN	2580154-02-3
Amount	1 mg
Quantity options	100 mg 10 mg 1 ea 1 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitor
Specific against	other
Purity	99.80
Citations	[1]International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 36, No. 2, 2022 \|[2]Ruoslahti Erkki, et al. Methods for treating pancreatic cancer and other solid tumors. WO2021226148.\|[3]Andrew Peter Dean, et al. Updated single institution outcome data from the first-in-human CEND-1 trial in metastatic pancreatic cancer. Journal of Clinical Oncology 2021 39:15_suppl, e16274-e16274\|[4]Harri A Järveläinen, et al. Assessment of the Pharmacokinetics, Disposition, and Duration of Action of the Tumour-Targeting Peptide CEND-1. Int J Mol Sci. 2023 Mar 16;24(6):5700.\|[5]Schmithals, C, et al. Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma. Cancer Res. 2015 Aug 1;75(15):3147-54.
Smiles	O=C1[C@@]2([H])N(C(CNC([C@@H](NC([C@@H](NC(CNC([C@@H](NC([C@H](CSSC[C@H](NC([C@@H](N1)CC(O)=O)=O)C(N)=O)NC(C)=O)=O)CCCNC(N)=N)=O)=O)CC(O)=O)=O)CCCCN)=O)=O)CCC2
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	CEND-1,iRGD,LSTA1
Shipping Condition	Cool pack
Available
Manufacturer - Type	Peptides
Manufacturer - Applications	Cancer-programmed cell death
Manufacturer - Targets	Complement System; Integrin
Shipping Temperature	Blue Ice
Storage Conditions	-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)
Molecular Weight	989.09
Product Description	Certepetide (CEND-1) is a bifunctional cyclic peptide (a.k.a. iRGD). Certepetide is a tumor-penetrating enhancer via RGD motif interaction with alphav-integrins and via activating NRP-1, and transforms the solid tumor microenvironment into a temporary agent conduit. Certepetide accumulates in tumors, and is used in the research of pancreatic cancer and other solid tumors[1][2][3].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 2.33 mg/mL (ultrasonic)\|H2O: ≥ 50 mg/mL
Manufacturer - Pathway	Cytoskeleton; Immunology/Inflammation
Clinical information	Phase 2

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-P3448-1mg-safety-datasheet.pdf